Informações:
Falhas:
ID
26053
Descrição
A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.; ODM derived from: https://clinicaltrials.gov/show/NCT00444587
Link
https://clinicaltrials.gov/show/NCT00444587
Palavras-chave
Versões (1)
- 05/10/2017 05/10/2017 -
Titular dos direitos
See clinicaltrials.gov
Transferido a
5 de outubro de 2017
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Breast Cancer NCT00444587
Eligibility Breast Cancer NCT00444587
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer NCT00444587
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Gender | Age
Item
female patients, >= 18 years of age;
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0001779 (UMLS CUI [2])
Secondary malignant neoplasm of female breast
Item
metastatic breast cancer;
boolean
C0346993 (UMLS CUI [1])
HER2 Overexpression Immunohistochemistry Positive | HER2 Overexpression FISH Positive
Item
her2 overexpression (ihc 3+ and/or fish positive);
boolean
C0069515 (UMLS CUI [1,1])
C1514559 (UMLS CUI [1,2])
C0021044 (UMLS CUI [1,3])
C1514241 (UMLS CUI [1,4])
C0069515 (UMLS CUI [2,1])
C1514559 (UMLS CUI [2,2])
C0162789 (UMLS CUI [2,3])
C1514241 (UMLS CUI [2,4])
C1514559 (UMLS CUI [1,2])
C0021044 (UMLS CUI [1,3])
C1514241 (UMLS CUI [1,4])
C0069515 (UMLS CUI [2,1])
C1514559 (UMLS CUI [2,2])
C0162789 (UMLS CUI [2,3])
C1514241 (UMLS CUI [2,4])
Disease Progression | First line Chemotherapy | Herceptin
Item
disease progression during or after previous 1st line chemotherapy + herceptin;
boolean
C0242656 (UMLS CUI [1])
C1708063 (UMLS CUI [2,1])
C0392920 (UMLS CUI [2,2])
C0338204 (UMLS CUI [3])
C1708063 (UMLS CUI [2,1])
C0392920 (UMLS CUI [2,2])
C0338204 (UMLS CUI [3])
Second line Chemotherapy Scheduled
Item
scheduled to receive 2nd line chemotherapy.
boolean
C1710038 (UMLS CUI [1,1])
C0392920 (UMLS CUI [1,2])
C0205539 (UMLS CUI [1,3])
C0392920 (UMLS CUI [1,2])
C0205539 (UMLS CUI [1,3])
Immunotherapy | Hormone Therapy
Item
concurrent immunotherapy or hormonal therapy;
boolean
C0021083 (UMLS CUI [1])
C0279025 (UMLS CUI [2])
C0279025 (UMLS CUI [2])
Anthracyclines | Part First line Chemotherapy | Second line Chemotherapy Planned
Item
anthracyclines as part of previous 1st line chemotherapy or planned 2nd line chemotherapy;
boolean
C0282564 (UMLS CUI [1])
C0449719 (UMLS CUI [2,1])
C1708063 (UMLS CUI [2,2])
C0392920 (UMLS CUI [2,3])
C1710038 (UMLS CUI [3,1])
C0392920 (UMLS CUI [3,2])
C1301732 (UMLS CUI [3,3])
C0449719 (UMLS CUI [2,1])
C1708063 (UMLS CUI [2,2])
C0392920 (UMLS CUI [2,3])
C1710038 (UMLS CUI [3,1])
C0392920 (UMLS CUI [3,2])
C1301732 (UMLS CUI [3,3])
Cardiotoxicity | First line Chemotherapy | Herceptin
Item
cardiac toxicity during previous 1st line chemotherapy + herceptin;
boolean
C0876994 (UMLS CUI [1])
C1708063 (UMLS CUI [2,1])
C0392920 (UMLS CUI [2,2])
C0338204 (UMLS CUI [3])
C1708063 (UMLS CUI [2,1])
C0392920 (UMLS CUI [2,2])
C0338204 (UMLS CUI [3])
Malignant Neoplasms
Item
history of other malignancy within last 5 years.
boolean
C0006826 (UMLS CUI [1])